Novavax (NVAX) Misses Q3 EPS, Revenue Beats; Guides to Low End

Novavax (NASDAQ: NVAX) reported Q3 EPS of ($2.15), $3.78 worse than the analyst estimate of $1.63. Revenue for the quarter came in at $735 million versus the consensus estimate of $623.9 million.

GUIDANCE:

Novavax sees FY2022 revenue of $2 billion, versus the consensus of $2.04 billion.

For earnings history and earnings-related data on Novavax (NVAX) click here.

You May Also Be Interested In

• Citrini flags overheating concerns as leverage, chip rally weigh on KOSPI
• VisionWave Rolls Out Combat-Ready Drones at the World’s Biggest Defense Show — and a Counter-Drone Interceptor to Match
• Bernstein SocGen Group Reiterates Outperform Rating on Hermes International (RMS:FP) (HESAY) after cautious commentary